400-859-2883
Your location:Home >News center >Wonderful moment

Intismeran Autogene (mRNA-4157) Phase 3 Results: Personalized Neoantigen mRNA Therapy

Release time:2026/8/25 0:57:52
Author:Huateng

Moderna and Merck’s mRNA-4157 (V940) met Phase 3 RFS and DMFS endpoints in melanoma, marking a major milestone for perso…

On August 19, 2026, Moderna and Merck announced positive topline results from the global Phase 3 INTerpath-001 study evaluating intismeran autogene (formerly V940 or mRNA-4157), an investigational individualized neoantigen mRNA therapy, in combination with pembrolizumab (KEYTRUDA) as adjuvant treatment in patients with completely resected Stage IIB-IV melanoma.

INTerpath-001 represents the first Phase 3 trial to report positive results for an individualized neoantigen therapy (INT) and an mRNA-based cancer therapy. The result marks an important milestone for mRNA technology, extending its clinical potential beyond infectious disease vaccines into personalized immunotherapy for solid tumors.

Cancer Vaccines Development: Shift to Individualized Neoantigen mRNA Therapy

The concept of therapeutic cancer vaccines is not new. Researchers have been exploring ways to stimulate the immune system to recognize and attack cancer cells since the 1990s.

However, clinical development has proven challenging. Several therapeutic cancer vaccine candidates, including Rintega, rocapuldencel-T and Prophage G-200, failed to demonstrate sufficient clinical benefit in late-stage development. To date, sipuleucel-T (PROVENGE) remains the only FDA-approved therapeutic cancer vaccine in the United States. Unlike conventional preventive vaccines, sipuleucel-T is an autologous cellular immunotherapy designed for patients with metastatic castration-resistant prostate cancer.

Tumor heterogeneity, immunosuppressive TMEs, and immune tolerance mechanisms pose significant challenges for cancer vaccine efficacy.

Earlier therapeutic cancer vaccine strategies also frequently focused on tumor-associated antigens rather than truly tumor-specific antigens. This can limit the ability of the immune system to distinguish cancer cells from healthy tissues.

Personalized neoantigen vaccines take a different approach by targeting mutation-derived peptides that are absent from normal tissues and therefore less constrained by immune tolerance.

The emergence of mRNA technology has provided a flexible platform for developing personalized cancer immunotherapies. Cancer mRNA vaccines are structurally based on specific tumor antigens, a technique which enables the patient’s immune system to become activated against cancer cells.

Intismeran autogene is an individualized neoantigen mRNA therapy designed and produced using a patient's tumor sample to identify the unique mutational signature, or "fingerprint," of their cancer and generate an anti-tumor immune response. Each therapy consists of a synthetic mRNA coding for up to 34 neoantigens and is tailored to the unique biology of an individual patient's tumor. Upon administration, the RNA-encoded neoantigen sequences are translated in the body and presented to the immune system, a key step in generating specific T-cell responses against cancer cells. Individualized neoantigen therapies are designed to train and activate an anti-tumor immune response based on the unique mutational signature of a patient's tumor. When combined with pembrolizumab, the approach is designed to both stimulate tumor-specific T-cell responses and reduce immune checkpoint-mediated suppression. 

Intismeran-autogene.jpg
Figure 1. Intismeran autogene, source: Merck official website

Phase 3 INTerpath-001 Results

The global, multicenter INTerpath-001 Phase 3 trial enrolled 1,137 patients with completely resected stage IIB-IV melanoma. Participants were randomized to receive either pembrolizumab alone or the combination of intismeran autogene and pembrolizumab.

The study met its primary endpoint of recurrence-free survival (RFS) and its key secondary endpoint of distant metastasis-free survival (DMFS). At a prespecified interim analysis, the combination of intismeran autogene and pembrolizumab demonstrated a statistically significant and clinically meaningful improvement in both RFS and DMFS compared with pembrolizumab alone. The companies have not yet disclosed the specific hazard ratios and P values, with detailed results expected to be presented at a future medical meeting. [2]

These Phase 3 findings build on the longer-term results from the Phase 2b KEYNOTE-942/mRNA-4157-P201 study.

At the 2026 ASCO Annual Meeting, five-year follow-up data showed that intismeran autogene plus pembrolizumab continued to provide sustained benefits compared with pembrolizumab alone. The combination reduced the risk of recurrence or death by 49% (HR 0.510) and the risk of distant metastasis or death by 59% (HR 0.411). [3]

The Race for Personalized mRNA Cancer Vaccines

The personalized neoantigen cancer vaccine field remains relatively early. Intismeran autogene is currently the first individualized neoantigen therapy and mRNA-based cancer therapy to report positive Phase 3 results.

BioNTech is also developing personalized mRNA cancer immunotherapies. Its lead individualized neoantigen candidate, autogene cevumeran (BNT122/RO7198457), is being developed in collaboration with Genentech and is being evaluated in randomized Phase 2 studies across several cancer types, including pancreatic ductal adenocarcinoma and colorectal cancer.

GRANITE 001 is a personalised tumour-specific neoantigen (TSNA) based cancer vaccine, that is being developed by Gritstone bio, with a leading Phase III program in metastatic colorectal cancer.

Conclusion

The positive Phase 3 INTerpath-001 results mark an important milestone for personalized cancer immunotherapy and mRNA technology and suggest that personalized neoantigen mRNA therapies may be moving from an experimental concept toward a clinically validated therapeutic platform, potentially opening a new chapter for precision immunotherapy in solid tumors.

LNP Delivery Systems in the mRNA Manufacturing

Lipid nanoparticles (LNPs) are a critical component of the mRNA manufacturing and delivery ecosystem. As the delivery system responsible for protecting mRNA and facilitating its cellular uptake, LNP technology plays an important role in determining the stability, delivery efficiency, and overall performance of mRNA therapeutics.

The development of LNP formulations requires specialized lipids and formulation technologies. Key lipid components typically include ionizable lipids, phospholipids, cholesterol, and PEG lipids. Among these, PEG lipids are essential for controlling particle size, stability, circulation characteristics, and other physicochemical properties of LNP formulations.

Huateng Pharma provides PEG derivatives and PEG lipids used in drug delivery and pharmaceutical research, supporting applications including lipid nanoparticles, liposomes, and other advanced drug delivery systems.

References:
[1] Ibragimova AA, Fedorov AA, Kirilenko KM, Choynzonov EL, Denisov EV, Patysheva MR. mRNA-Based Personalized Cancer Vaccines: Opportunities, Challenges and Outcomes. Acta Naturae. 2025 Oct-Dec;17(4):17-37. doi: 10.32607/actanaturae.27707. PMID: 41479562; PMCID: PMC12755870.
[2] https://www.merck.com/news/merck-and-moderna-announce-phase-3-interpath-001-trial-of-intismeran-autogene-plus-keytruda-met-endpoints-of-recurrence-free-survival-rfs-and-distant-metastasis-free-survival-dmfs-in-patient/ Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV Melanoma
[3] https://www.asco.org/abstracts-presentations/259570?utm_source=chatgpt.com Individualized neoantigen therapy intismeran autogene (intismeran) plus pembrolizumab (pembro) in resected melanoma: 5-year update of the KEYNOTE-942 study.